Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inhibitors (PARPi) have revolutionized disease management of patients with homologous recombination (HR) DNA repair-deficient HGSOC. However, acquired resistance to PARPi by complex mechanisms including HR restoration and stabilisation of replication forks is a major challenge in the clinic. Here, we demonstrate CX-5461, an inhibitor of RNA polymerase I transcription of ribosomal RNA genes (rDNA), induces replication stress at rDNA leading to activation of DNA damage response and DNA damage involving MRE11-dependent degradation of replication forks. CX-5461 cooperates with PARPi in exacerbating DNA damage and enhances synthetic lethal interactions of PARPi with HR deficiency in HGSOC-patient-derived xenograft (PDX) in vivo. We demonstrate CX-5461 has a different sensitivity spectrum to PARPi and destabilises replication forks irrespective of HR pathway status, overcoming two well-known mechanisms of resistance to PARPi. Importantly, CX-5461 exhibits single agent efficacy in PARPi-resistant HGSOC-PDX. Further, we identify CX-5461-sensitivity gene expression signatures in primary and relapsed HGSOC. Therefore, CX-5461 is a promising therapy alone and in combination therapy with PARPi in HR-deficient HGSOC. CX-5461 is also an exciting treatment option for patients with relapsed HGSOC tumors that have poor clinical outcome.

[1]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[2]  S. Fox,et al.  Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma , 2018, Nature Communications.

[3]  Joseph V Bonventre,et al.  Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. , 2018, Cancer discovery.

[4]  J. Bartek,et al.  High speed of fork progression induces DNA replication stress and genomic instability , 2018, Nature.

[5]  Y. Drew,et al.  Emerging treatment options for ovarian cancer: focus on rucaparib , 2017, International journal of women's health.

[6]  George Thomas,et al.  Ribosome biogenesis in cancer: new players and therapeutic avenues , 2017, Nature Reviews Cancer.

[7]  R. Rabadán,et al.  Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers. , 2017, Molecular cell.

[8]  Zachary C. Dobbin,et al.  Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer , 2017, Clinical Cancer Research.

[9]  James X. Sun,et al.  Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. , 2017, Cancer discovery.

[10]  J. Zuber,et al.  Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. , 2017, Blood.

[11]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[12]  Jian Xian,et al.  CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours , 2017, Nature Communications.

[13]  J. George,et al.  A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. , 2017, Cancer research.

[14]  A. Ashworth,et al.  PARP inhibitor combination therapy. , 2016, Critical reviews in oncology/hematology.

[15]  S. Cantor,et al.  Erratum: Replication fork stability confers chemoresistance in BRCA-deficient cells , 2016, Nature.

[16]  K. Khanna,et al.  Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling , 2016, Oncotarget.

[17]  S. Cantor,et al.  Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells , 2016, Nature.

[18]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[19]  Andrés Aguilera,et al.  R loops: new modulators of genome dynamics and function , 2015, Nature Reviews Genetics.

[20]  P. Brown,et al.  rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis , 2015, Oncotarget.

[21]  B. McStay,et al.  A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage , 2015, Genes & development.

[22]  C. Scott,et al.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jason Ellul,et al.  A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes , 2015, Genome research.

[24]  Stephen J. Elledge,et al.  Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair , 2015, Nature.

[25]  K. Peltonen,et al.  Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress , 2014, Molecular Cancer Therapeutics.

[26]  R. Hannan,et al.  Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease , 2014, Cell & Bioscience.

[27]  S. Fox,et al.  Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts , 2014, Molecular oncology.

[28]  Ralph R. Weichselbaum,et al.  DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy , 2014, Science Translational Medicine.

[29]  G. Mills,et al.  Genome-wide Transcriptome Profiling of Homologous Recombination DNA Repair , 2014, Nature Communications.

[30]  C. Bieberich,et al.  A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. , 2014, Cancer cell.

[31]  D. Bowtell,et al.  Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. , 2013, European journal of cancer.

[32]  R. Hannan,et al.  The nucleolus: an emerging target for cancer therapy. , 2013, Trends in molecular medicine.

[33]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[34]  A. Ashworth,et al.  Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor , 2013, The Journal of pathology.

[35]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[36]  Carleen Cullinane,et al.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.

[37]  M. Hottiger,et al.  Inheritance of silent rDNA chromatin is mediated by PARP1 via noncoding RNA. , 2012, Molecular cell.

[38]  D. Cortez,et al.  Analysis of protein dynamics at active, stalled, and collapsed replication forks. , 2011, Genes & development.

[39]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[40]  H. Johnsen,et al.  Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers , 2011, PloS one.

[41]  R. Hannan,et al.  Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.

[42]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[43]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[44]  Tom Moss,et al.  UBF levels determine the number of active ribosomal RNA genes in mammals , 2008, The Journal of cell biology.

[45]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[46]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[47]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Gordon K. Smyth,et al.  Use of within-array replicate spots for assessing differential expression in microarray experiments , 2005, Bioinform..

[49]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[50]  R. Pearson,et al.  Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. , 2016, Cancer discovery.